Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study | Zendy

Joseph J. Eron | Zendy; Bonaventura Clotet | Zendy; J. Durant | Zendy; Christine Katlama | Zendy; Princy Kumar | Zendy; Adriano Lazzarin | Zendy; Isabelle PoizotMartin | Zendy; Gary Richmond | Zendy; Vincent Soriano | Zendy; Mounir AitKhaled | Zendy; Tamio Fujiwara | Zendy; Jenny Huang | Zendy; Sherene Min | Zendy; Cindy Vavro | Zendy; Jane Yeo | Zendy; Sharon Walmsley | Zendy; Joseph Cox | Zendy; Jacques Reynes | Zendy; Philippe Morlat | Zendy; Daniel Vittecoq | Zendy; JeanMichel Livrozet | Zendy; Pompeyo Viciana Fernández | Zendy; José M. Gatell | Zendy; Edwin DeJesus | Zendy; Jerome DeVente | Zendy; Jacob Lalezari | Zendy; Lewis McCurdy | Zendy; Louis A. Sloan | Zendy; Benjamin Young | Zendy; Anthony LaMarca | Zendy; Trevor Hawkins | Zendy

Open Access

Safety and Efficacy of Dolutegravir in Treatment-Experienced Subjects With Raltegravir-Resistant HIV Type 1 Infection: 24-Week Results of the VIKING Study

Author(s) -

Joseph J. Eron,

Bonaventura Clotet,

J. Durant,

Christine Katlama,

Princy Kumar,

Adriano Lazzarin,

Isabelle PoizotMartin,

Gary Richmond,

Vincent Soriano,

Mounir AitKhaled,

Tamio Fujiwara,

Jenny Huang,

Sherene Min,

Cindy Vavro,

Jane Yeo,

Sharon Walmsley,

Joseph Cox,

Jacques Reynes,

Philippe Morlat,

Daniel Vittecoq,

JeanMichel Livrozet,

Pompeyo Viciana Fernández,

José M. Gatell,

Edwin DeJesus,

Jerome DeVente,

Jacob Lalezari,

Lewis McCurdy,

Louis A. Sloan,

Benjamin Young,

Anthony LaMarca,

Trevor Hawkins

Publication year - 2012

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jis750

Subject(s) - dolutegravir , raltegravir , regimen , cohort , medicine , viral load , integrase inhibitor , elvitegravir , dosing , virology , human immunodeficiency virus (hiv) , antiretroviral therapy

Dolutegravir (DTG; S/GSK1349572), a human immunodeficiency virus type 1 (HIV-1) integrase inhibitor, has limited cross-resistance to raltegravir (RAL) and elvitegravir in vitro. This phase IIb study assessed the activity of DTG in HIV-1-infected subjects with genotypic evidence of RAL resistance.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research